Subcutaneous immunoglobulins: Product characteristics and their role in primary immunodeficiency disease

Isaac Melamed*, Alessandro Testori, Zvi Spirer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Research on the role of subcutaneous immunoglobulin in primary immunodeficiency disease (PIDD) is ongoing. We analyzed pivotal studies for four subcutaneous immunoglobulin products: IGSC 10% (Gammagard® Liquid), IGIV-C 10% (Gamunex®-C), IGSC 16% (Vivaglobin®) and IGSC 20% (Hizentra®). To identify similarities and differences between products, we examined infusion parameters, adverse event profiles and improvements in tolerability over time. Maximum volume infused was 30 mL/site for IGSC 10%, 34 mL/site for IGIV-C 10%, 15 mL/site for IGSC 16% and 25 mL/site for IGSC 20%. Maximum number of simultaneous infusion sites was 10 for IGSC 10%, 8 for IGIV-C 10%, 6 for IGSC 16% and 4 for IGSC 20%. Local adverse reaction rate per infusion was 0.02 for IGSC 10%, 0.59 for IGIV-C, 0.49 for IGSC 16% and 0.58 for IGSC 20%. IGSC products have similar efficacy profiles; however, their tolerability profiles vary. Reasons for these differences are unknown and warrant further research.

Original languageEnglish
Pages (from-to)451-461
Number of pages11
JournalInternational Reviews of Immunology
Issue number6
StatePublished - Dec 2012
Externally publishedYes


  • Adverse drug reactions
  • Immunoglobulin G
  • Immunologic deficiency syndrome
  • Intravenous immunoglobulin therapy
  • Primary immunodeficiency disease


Dive into the research topics of 'Subcutaneous immunoglobulins: Product characteristics and their role in primary immunodeficiency disease'. Together they form a unique fingerprint.

Cite this